FDA Approved, Resolute Onyx 2.0 mm DES Technology Tackles Clinical Challenge of Treating Coronary Artery Disease in Previously Untreatable Patients DUBLIN – February 26, 2018 – Designed specifically for small vessels, Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute […]
Tag: Medtronic
Boston Scientific’s Ranger DCB and Medtronic’s In.Pact Admiral DCB – Head to Head
This first of it’s kind trial compares two leading DCB technologies. Boston Scientific’s drug-coated balloon goes up against Medtronic’s DCB in first-of-its-kind trial JANUARY 31, 2018 BY SARAH FAULKNER, Drug Delivery Business NEws Top-line results from a head-to-head trial comparing Boston Scientific‘s (NYSE:BSX) Ranger drug-coated balloon and Medtronic‘s (NYSE:MDT) In.Pact Admiral DCB found no […]
Medtronic Closes $28M Purchase of QT Vascular’s Chocolate PTA Balloon Catheter
Medtronic Completes the Purchase of QT Vascular’s Chocolate PTA Balloon Catheter Highlights: – Medtronic completes the purchase of the Company’s non-drug coated Chocolate® PTA balloon catheter – The completion of this purchase validates the value of this internally developed specialty PTA to improve outcomes in patients with peripheral artery disease PLEASANTON, Calif., […]
Medtronic Shows Off IN.PACT Global Critical Limb Ischemia Study Data
IN.PACT Admiral Demonstrates Consistent and Durable Outcomes in New Two-Year Japan Data and IN.PACT Global Critical Limb Ischemia Cohort Analysis Data Presented at LINC 2018 Highlight IN.PACT Admiral as Safe and Effective Treatment Option in PAD DUBLIN and LEIPZIG – January 30, 2018 – Medtronic (NYSE: MDT) today added to its robust […]
Medtronic Launches IDE Study to Evaluate the Abre(TM) Venous Self-Expanding Stent System in Patients with Deep Venous Disease
Study to Enroll Subjects at up to 35 Sites Across the U.S. and Europe DUBLIN – January 26, 2018 – Medtronic plc (NYSE: MDT) today announced the initiation of its investigational device exemption (IDE) study for the Abre(TM) venous self-expanding stent system. The ABRE IDE Study will evaluate the safety and […]
MEDTRONIC RECEIVES FDA CLEARANCE FOR RIPTIDE(TM) ASPIRATION SYSTEM
DUBLIN – January 16, 2018 – Medtronic plc (NYSE:MDT) today announced that the company’s Neurovascular business unit received U.S. Food and Drug Administration (FDA) clearance of the Riptide(TM) Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. The Riptide Aspiration System is designed to retrieve thrombus […]
Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2018
DUBLIN – December 8, 2017 – The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2018 third quarter cash dividend of $0.46 per ordinary share, representing a 7 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company […]
Medtronic Announces FDA Approval and U.S. Launch of Next Generation Pacemakers
DUBLIN – November 20, 2017 – Medtronic (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. commercial launch for its portfolio of Azure(TM) pacemakers with BlueSync(TM)technology. Available in both single chamber and dual chamber models, the Azure XT MRI and Azure S MRI pacemakers offer improved longevity, estimated at 13.7 […]
Medtronic gains new CPT codes for Venous device in 2018
Medtronic’s VenaSeal Closure System Receives New CPT Codes By Endovascular Today November 13, 2017—Medtronic has advised that their VenaSeal closure system received a favorable new CPT code as a Level 4 vascular procedure as part of the calendar year 2018 Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment and Ambulatory Surgical Center […]
Medtronic Evolut(TM) PRO TAVR System with Advanced Sealing Maintains Excellent Outcomes Over Time
DUBLIN and DENVER – November 2, 2017 – Medtronic plc (NYSE:MDT) today presented new data at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting showcasing the excellent clinical performance of the Evolut(TM) Transcatheter Aortic Valve Replacement (TAVR) platform. Six-month data from the newest-generation Evolut PRO System demonstrated continued benefits of its unique valve […]
Recent
Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
PARAMOUNT, the First Randomized Trial of AI-Enabled Plaque-Based Care, Meets Primary Endpoint in Late-Breaking Results at AHA 2026
AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Popular
- No commented posts yet